Thermo Fisher Scientific Inc., a prominent U.S. clinical research and life science company with annual revenues exceeding $40 billion, has injected ₹160 crore into its Bengaluru operations. This substantial investment aims to significantly bolster its research and development capabilities, driving innovation in the crucial fields of antibody research and manufacturing.
The expanded R&D Centre of Excellence, spanning 37,000 square feet, is equipped with state-of-the-art automation and analytical platforms. These advanced tools will facilitate cutting-edge work in immunoassay development, protein analysis, and cell-based studies. This expansion is also set to create more than 100 new jobs, further enriching the company’s existing team of 1,400 professionals in the vibrant Indian city.
Priyank Kharge, Karnataka’s Minister for Electronics, IT & Biotechnology, and Rural Development & Panchayat Raj, lauded the development. He emphasized that this new facility will significantly enhance the state’s capacity to contribute to India’s broader vision for biotechnology. Minister Kharge highlighted Karnataka’s established reputation as a dynamic hub for life sciences, asserting that Thermo Fisher’s expansion serves as a strong endorsement of the state’s ongoing commitment to this strategic sector.
Karnataka continues to be a powerhouse in India’s life sciences landscape, contributing over 10% to the nation’s pharmaceutical revenues and approximately 60% to its biotechnology revenues. The state boasts more than 221 formulation units, 74 bulk drug units, and 35 Contract Research Organizations (CROs). With a bioeconomy valued at around $31 billion and growing at a robust 10.7%, Karnataka reinforces its position as a global leader in scientific innovation.